Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 1
Submit an article Journal homepage
286
Views
56
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

Eva Kimby Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSwedenCorrespondence[email protected]
,
Jesper Jurlander Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
,
Christian Geisler Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
,
Hans Hagberg Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
,
Harald Holte Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
,
Tuula Lehtinen Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
,
Björn Östenstad Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
,
Mads Hansen Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
,
Anders Österborg Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
,
Ola Lindén Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
,
Christer Sundström Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
&
On Behalf Of The Nordic Lymphoma Group Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden
 show all
Pages 102-112 | Received 21 Jun 2007, Accepted 25 Sep 2007, Published online: 01 Jul 2009

Citations (56)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (15)

E. Leich, Marianne Brodtkorb, T. Schmidt, M. Altenbuchinger, Ole Christian Lingjærde, S. Lockmer, H. Holte, T. Nedeva, T. Grieb, B. Sander, C. Sundström, R. Spang, E. Kimby & A. Rosenwald. (2023) Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy. Leukemia & Lymphoma 0:0, pages 1-11.
Read now
Cecilie E Kiserud, Sandra Lockmer, Idun Baerug, Alv A Dahl, Eva Kimby & Bjørn Østenstad. (2023) Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data. Leukemia & Lymphoma 64:2, pages 349-355.
Read now
Elena García-Martínez, Melody Smith, Aitziber Buqué, Fernando Aranda, Francisco Ayala de la Peña, Alejandra Ivars, Manuel Sanchez Cánovas, Ma Angeles Vicente Conesa, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology 7:6.
Read now
Eva Kimby, Björn Östenstad, Peter Brown, Hans Hagberg, Martin Erlanson, Harald Holte, Ola Linden, Ann-Sofie Johansson, Tomas Ahlgren, Karin Wader, Björn Engelbrekt Wahlin, Jan Delabie & Christer Sundström. (2015) Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leukemia & Lymphoma 56:9, pages 2598-2607.
Read now
Henri-Alexandre Michaud, Jean-François Eliaou, Virginie Lafont, Nathalie Bonnefoy & Laurent Gros. (2014) Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. OncoImmunology 3:9.
Read now
Björn Engelbrekt Wahlin, Christer Sundström, Birgitta Sander, Birger Christensson, Åsa Jeppsson-Ahlberg, Eric Hjalmarsson, Harald Holte, Bjørn Østenstad, Peter D. Brown, Erlend Bremertun Smeland & Eva Kimby. (2014) Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leukemia & Lymphoma 55:2, pages 288-295.
Read now
Hans Carl Hasselbalch. (2011) A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Review of Hematology 4:6, pages 637-655.
Read now
Reem Karmali, Melissa L. Larson, James E. Wooldridge, Stephanie A. Gregory, Teresa O'Brien, Jamile M. Shammo, Katherine Bueschel & Parameswaran Venugopal. (2011) Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leukemia & Lymphoma 52:11, pages 2097-2104.
Read now
David M. Goldenberg, Franck Morschhauser & William A. Wegener. (2010) Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leukemia & Lymphoma 51:5, pages 747-755.
Read now
Andrew P. Grigg, Janey Stone, Alvin D. Milner, Anthony P. Schwarer, Max Wolf, H. Miles Prince, John Seymour, Devinder Gill, David Ellis & John Bashford. (2010) Phase II study of autologous stem cell transplant using busulfan–melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leukemia & Lymphoma 51:4, pages 641-649.
Read now
Peter McLaughlin & Stefano Sacchi. (2009) Interferon: Does it still have a role in the 21st century?. Leukemia & Lymphoma 50:10, pages 1562-1563.
Read now
S. M. Smith, J. Johnson, B. D. Cheson, G. Canellos, G. Petroni, M. Oken, D. Duggan, D. Hurd, J. P. Gockerman, B. Parker, J. Prchal & B. A. Peterson. (2009) Recombinant interferon-α2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leukemia & Lymphoma 50:10, pages 1606-1617.
Read now
Claudia Stolz & Martin Schuler. (2009) Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leukemia & Lymphoma 50:6, pages 873-885.
Read now
Kristin Feuerlein, Emanuele Zucca & Michele Ghielmini. (2009) First-line treatment of follicular lymphoma–a patient-oriented algorithm. Leukemia & Lymphoma 50:3, pages 325-334.
Read now
Martin Dreyling. (2008) Combination of biologicals in indolent lymphoma: Finally the end of chemotherapy era in indolent lymphoma?. Leukemia & Lymphoma 49:1, pages 8-9.
Read now

Articles from other publishers (41)

Alden A. Moccia, Christian TavernaSämi Schär, Anna Vanazzi, Stéphanie RondeauFelicitas HitzWalter Mingrone, Thomas Pabst, Lidija CevreskaAuro del Giglio, Johann Raats, Daniel RauchDaniel A. Vorobiof, Andreas Lohri, Céline RuegseggerChristine Biaggi RudolfCorinne RusterholzStefanie Hayoz, Michele GhielminiEmanuele Zucca. (2020) Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Advances 4:23, pages 5951-5957.
Crossref
Eva Kimby, Sandra Lockmer, Harald Holte, Hans Hagberg, Björn E. Wahlin, Peter Brown & Bjørn Østenstad. (2020) The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy. British Journal of Haematology 191:5, pages 738-747.
Crossref
Henna-Riikka Junlén, Sandra Lockmer, Eva Kimby & Björn Engelbrekt Wahlin. (2020) Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy. Annals of Hematology 99:10, pages 2357-2366.
Crossref
Sandra Lockmer, Weicheng Ren, Marianne Brodtkorb, Bjørn Østenstad, Björn E. Wahlin, Qiang Pan‐Hammarström & Eva Kimby. (2019) M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy. British Journal of Haematology 188:2, pages 259-267.
Crossref
Joseph M. Tuscano, Emanual Maverakis, Susan Groshen, Denice Tsao-Wei, Guillaume Luxardi, Alexander A. Merleev, Anne Beaven, John F. DiPersio, Leslie Popplewell, Robert Chen, Mark Kirschbaum, Mark A. Schroeder & Edward M. Newman. (2019) A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clinical Cancer Research 25:23, pages 7004-7013.
Crossref
Emanuele Zucca, Stephanie RondeauAnna VanazziBjørn ØstenstadUlrich J. M. MeyDaniel RauchBjörn E. WahlinFelicitas Hitz, Micaela HernbergAnn-Sofie JohanssonPeter de Nully Brown, Hans HagbergAndrés J. M. Ferreri, Andreas LohriUrban Novak, Thilo Zander, Hanne BersvendsenMario BargetziWalter Mingrone, Fatime Krasniqi, Stefan Dirnhofer, Stefanie Hayoz, Hanne HawleSimona Berardi Vilei, Michele GhielminiEva Kimby. (2019) Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood 134:4, pages 353-362.
Crossref
Sandra LockmerBjørn ØstenstadHans HagbergHarald HolteBjörn Engelbrekt WahlinKarin Fahl WaderKarin Ekström SmedbyPeter BrownEva Kimby. (2019) Reply to M. Sorigue et al. Journal of Clinical Oncology 37:9, pages 759-760.
Crossref
Sandra LockmerBjørn ØstenstadHans HagbergHarald HolteAnn-Sofie JohanssonBjörn Engelbrekt WahlinKarin Fahl WaderChloé Beate SteenPeter MeyerMartin MaisenhølderKarin Ekström SmedbyPeter BrownEva Kimby. (2018) Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. Journal of Clinical Oncology 36:33, pages 3315-3323.
Crossref
R. Karmali, E. Kimby, M. Ghielmini, I.W. Flinn, L.I. Gordon & E. Zucca. (2018) Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. Annals of Oncology 29:2, pages 332-340.
Crossref
Caroline H. Riley, Marie K. Brimnes, Morten Hansen, Morten Krogh Jensen, Hans C. Hasselbalch, Lasse Kjaer, Per thor Straten & Inge Marie Svane. (2016) Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. European Journal of Haematology 97:1, pages 83-92.
Crossref
GABRIEL G. VEGA, LUZ ARELI FRANCO-CEA, SARA HUERTA-YEPEZ, HÉCTOR MAYANI, SHERIE L. MORRISON, BENJAMIN BONAVIDA & MARIO I. VEGA. (2015) Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy. International Journal of Oncology 47:5, pages 1735-1748.
Crossref
Frederick Arce Vargas & Sergio A. Quezada. (2015) Fc?-receptor tag team boosts anti-tumor immunity. Trends in Immunology 36:7, pages 388-389.
Crossref
David J. DiLillo & Jeffrey V. Ravetch. (2015) Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell 161:5, pages 1035-1045.
Crossref
H R Junlén, S Peterson, E Kimby, S Lockmer, O Lindén, H Nilsson-Ehle, M Erlanson, H Hagberg, A Rådlund, O Hagberg & B E Wahlin. (2014) Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia 29:3, pages 668-676.
Crossref
L. Arcaini, D. Vallisa, S. Rattotti, V.V. Ferretti, A.J.M. Ferreri, P. Bernuzzi, M. Merli, M. Varettoni, A. Chiappella, A. Ambrosetti, A. Tucci, C. Rusconi, C. Visco, M. Spina, G. Cabras, S. Luminari, M. Tucci, P. Musto, M. Ladetto, F. Merli, C. Stelitano, A. d'Arco, L. Rigacci, A. Levis, D. Rossi, P. Spedini, S. Mancuso, D. Marino, R. Bruno, L. Baldini & A. Pulsoni. (2014) Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Annals of Oncology 25:7, pages 1404-1410.
Crossref
Sinziana Radesi-Sarghi, Flavie Arbion, Caroline Dartigeas, Martine Delain, Lotfi Benboubker, Olivier Hérault, Philippe Colombat & Emmanuel Gyan. (2013) Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years’ experience in a single centre. Annals of Hematology 93:1, pages 147-156.
Crossref
Lei ZhaoQin TongWeizhu QianBohua LiDapeng ZhangTuo Fu, Shuyan Duan, Xueguang Zhang, Jian ZhaoJianxin DaiHao WangSheng HouYajun Guo. (2013) Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP. Blood 122:26, pages 4230-4236.
Crossref
Dongsheng Xu, Andrew Staedman & Luwen Zhang. (2013) CD20 Antibody Primes B Lymphocytes for Type I Interferon Production. PLoS ONE 8:6, pages e67900.
Crossref
Fabio Gentilini, Maria E. Turba & Monica Forni. (2013) Retrospective monitoring of minimal residual disease using hairpin-shaped clone specific primers in B-cell lymphoma affected dogs. Veterinary Immunology and Immunopathology 153:3-4, pages 279-288.
Crossref
Eva Kimby. (2012) Biological Therapy Doublets: Pairing Rituximab with Interferon, Lenalidomide, and Other Biological Agents in Patients with Follicular Lymphoma. Current Hematologic Malignancy Reports 7:3, pages 221-227.
Crossref
Holbrook E Kohrt, Roch Houot, Aurélien Marabelle, Hearn Jay Cho, Keren Osman, Matthew Goldstein, Ronald Levy & Joshua Brody. (2012) Combination strategies to enhance antitumor ADCC. Immunotherapy 4:5, pages 511-527.
Crossref
B E Wahlin, B Sander, B Christensson, B Østenstad, H Holte, P D Brown, C Sundström & E Kimby. (2012) Entourage: the immune microenvironment following follicular lymphoma. Blood Cancer Journal 2:1, pages e52-e52.
Crossref
Liat Vidal, Anat Gafter-Gvili, Gilles Salles, Martin H. Dreyling, Michele Ghielmini, Shu-Fang Hsu Schmitz, Ruth Pettengell, Mathias Witzens-Harig & Ofer Shpilberg. (2011) Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. JNCI: Journal of the National Cancer Institute 103:23, pages 1799-1806.
Crossref
Roswitha Forstpointner & Martin Dreyling. (2011) Rituximab Maintenance Versus Radioimmunotherapy Consolidation in Follicular Lymphoma: Which, When, and for Whom?. Current Hematologic Malignancy Reports 6:4, pages 207-215.
Crossref
Edmund A. RossiDiane L. Rossi, Thomas M. Cardillo, Rhona Stein, David M. Goldenberg & Chien-Hsing Chang. (2011) Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers. Blood 118:7, pages 1877-1884.
Crossref
Björn Engelbrekt Wahlin, Christer Sundström, Harald Holte, Hans Hagberg, Martin Erlanson, Herman Nilsson-Ehle, Ola Lindén, Marie Nordström, Bjørn Østenstad, Christian H. Geisler, Peter de Nully Brown, Tuula Lehtinen, Martin Maisenhölder, Anne M. Tierens, Birgitta Sander, Birger Christensson & Eva Kimby. (2011) T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab. Clinical Cancer Research 17:12, pages 4136-4144.
Crossref
Riad Abès & Jean-Luc Teillaud. (2011) Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer and Metastasis Reviews 30:1, pages 111-124.
Crossref
Roch Houot, Holbrook Kohrt, Matthew J. Goldstein & Ronald Levy. (2011) Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer and Metastasis Reviews 30:1, pages 97-109.
Crossref
Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara J Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian K Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Chris Cameron, Michael PT Lunn, Peter Tugwell & Rachelle Buchbinder. (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2016:4.
Crossref
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals 26:1, pages 1-64.
Crossref
Ali Al-Ameri, Mohamad Cherry, Aref Al-Kali & Alessandra Ferrajoli. (2010) The Role of Monoclonal Antibodies in the Management of Leukemia. Pharmaceuticals 3:10, pages 3258-3274.
Crossref
Giovanni MartinelliShu-Fang Hsu SchmitzUrs UtigerThomas CernyUrs HessSimona BassiEmmie OkkingaRoger StuppRolf StahelMarc HeizmannDaniel VorobiofAndreas LohriPierre-Yves DietrichEmanuele ZuccaMichele Ghielmini. (2010) Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98. Journal of Clinical Oncology 28:29, pages 4480-4484.
Crossref
Edmund A. Rossi, Diane L. Rossi, Rhona Stein, David M. Goldenberg & Chien-Hsing Chang. (2010) A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells. Cancer Research 70:19, pages 7600-7609.
Crossref
Riad Abès, Emmanuelle Gélizé, Wolf Herman Fridman & Jean-Luc Teillaud. (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116:6, pages 926-934.
Crossref
Caiyun XuanKristopher K. Steward, John M. Timmerman & Sherie L. Morrison. (2010) Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 115:14, pages 2864-2871.
Crossref
Shu-qing Lü, Jian-min Yang, Xian-min Song, Li Chen, Wei-ping Zhang, Xiao-qian Xu, Xiong Ni, Chong-mei Huang, Yi He & Jian-min Wang. (2010) CHOP-like regimen in combination with rituximab and peginterferon alpha-2b in newly-diagnosed diffuse large B-cell Non-Hodgkin’s lymphoma: Experience in a Chinese center. Clinical Oncology and Cancer Research 7:2, pages 103-109.
Crossref
Fabio Gentilini, Maria Elena Turba, Claudia Calzolari, Stefano Cinotti, Monica Forni & Augusta Zannoni. (2010) Real-time quantitative PCR using hairpin-shaped clone-specific primers for minimal residual disease assessment in an animal model of human non-Hodgkin lymphoma. Molecular and Cellular Probes 24:1, pages 6-14.
Crossref
Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein & Chien-Hsing Chang. (2009) CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 114:18, pages 3864-3871.
Crossref
David Goldstein, Robert Jones, Richard V. Smalley & Ernest C. Borden. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 277 301 .
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref
Mathias Rummel. (2008) Considerations with Newer Regimens for Indolent Non–Hodgkin Lymphoma. Clinical Lymphoma and Myeloma 8, pages S128-S136.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.